The estimated Net Worth of David Bench is at least 302 千$ dollars as of 14 June 2022. Mr. Bench owns over 3,500 units of Enzo Biochem stock worth over 6,660$ and over the last 5 years he sold ENZ stock worth over 0$. In addition, he makes 295,670$ as Chief Financial Officer、 Principal Accounting Officer at Enzo Biochem.
David has made over 1 trades of the Enzo Biochem stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 3,500 units of ENZ stock worth 7,525$ on 14 June 2022.
The largest trade he's ever made was buying 3,500 units of Enzo Biochem stock on 14 June 2022 worth over 7,525$. On average, David trades about 583 units every 0 days since 2020. As of 14 June 2022 he still owns at least 6,000 units of Enzo Biochem stock.
You can see the complete history of Mr. Bench stock trades at the bottom of the page.
David A. Bench serves as Chief Financial Officer, Principal Accounting Officer of the Company. Mr. Bench has over 23 years of financial experience as a Chief Financial Officer, investment banker, research analyst, and financial advisor. He most recently served as Chief Financial Officer of ELLKAY, LLC, a healthcare information technology company servicing diagnostic laboratories, electronic medical record providers, payers, hospital/health systems and ambulatory practices. Mr. Bench was also Founder and President of DBC Group, Corp., an advisory and consulting firm based in New York City, where he assisting both public and private global corporations with cash flow management, operational performance, strategic growth planning, capital structure, valuation analysis, as well as budgeting and expense control. He previously held the position of senior investment banker at Arete Wealth Management, where he covered the telecommunications, media and technology industries. Earlier in his career, Mr. Bench was a Vice President of Institutional Equity Research at Arnhold and S. Bleichroeder in New York and in the Mergers & Acquisitions Group within the Investment Banking division of Lazard Fréres L.L.C. He received his Bachelor’s degree in Economics from Brandeis University and his Master’s degree in International Economics and Finance from the International Business School at Brandeis University. Mr. Bench received his Series 7, 63, 79, 86, and 87 securities licenses from the Financial Industry Regulatory Authority (FINRA).
As the Chief Financial Officer、 Principal Accounting Officer of Enzo Biochem, the total compensation of David Bench at Enzo Biochem is 295,670$. There are 7 executives at Enzo Biochem getting paid more, with Elazar Rabbani having the highest compensation of 1,487,800$.
David Bench is 47, he's been the Chief Financial Officer、 Principal Accounting Officer of Enzo Biochem since 2019. There are 14 older and no younger executives at Enzo Biochem. The oldest executive at Enzo Biochem, Inc. is Dr. Elazar Rabbani Ph.D., 78, who is the Co-Founder, Chairman, Chief Scientific Officer & Sec..
David's mailing address filed with the SEC is C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK, NY, 1002.
Over the last 22 years, insiders at Enzo Biochem have traded over 2,615,763$ worth of Enzo Biochem stock and bought 1,070,494 units worth 3,103,461$ . The most active insiders traders include Bradley Louis Radoff、Management Corp Harbert Dis...、Elazar Rabbani. On average, Enzo Biochem executives and independent directors trade stock every 127 days with the average trade being worth of 59,099$. The most recent stock trade was executed by Kara Cannon on 21 February 2024, trading 10,640 units of ENZ stock currently worth 11,810$.
enzo biochem inc is a financial services company located in 60 executive blvd, farmingdale, new york, united states.
Enzo Biochem executives and other stock owners filed with the SEC include: